|
 Acomplia
(Rimonabant)
Rimonabant is certified for the treatment of predominance.
According to whether humans are actively (work, sport) or relaxed and passive (meal, sleep), the bodily functions are regulated by different parts unconscious nervous systems.
A part of this system is the Endocannabinoid in such a way specified system. It steers among other things the energy balance, the sugar and the fat metabolism as well as the body weight. Besides it plays a role with the desire on very sweet or very fat food.
The Endocannabinoid system is activated, if a hunger feeling begins. If this system is falsely active continuously, feels the concerning increases hunger and many more than necessarily eats.
Rimonabant is a CB1-Rezeptor blocker. It normalizes the overactivity of the Endocannabinoid of system.
Rimonabant should be used only with strong predominance (BMI ≥ 30), if calorie-poor food, change of the eating habits and the movement did not have the desired effect and additional factors of risk for heart cycle illnesses to exist as for instance diabetes type of 2 or high blood fat values.
Side effects of Acomplia
The most important, well-known side effects are listed. They can occur, do not have however not, since each humans respond differently to medicines.
Sometimes humans react allergisch to medicines. If you should feel signs of a allergischen reaction, inform immediately your physician or pharmacist.
* Infection of the respiratory system (very frequent)
* Nausea (very frequent)
* Failure (frequent)
* Change of tendency with depressive detuning (frequent)
* Feeling of dizziness and memory loss (frequent)
* Hot flush (frequent)
* Vomit (frequently)
* Itching and excessive sweating (frequent)
* Muscle cramps (frequent)
* Ermüdbarkeit (frequent)
* Joint verse dipping (frequent)
--
Areas of application of Acomplia
* Predominance (BMI = 30)
Acomplia of warning references!
* With patients with reduced liver or kidney function caution is required.
* So far only patients were treated, who were younger than 75 years.
* Patients with Laktoseintoleranz may not take the medicine, since it contains Laktose.
* So far patients were treated maximally two years, possible long-term effects are unknown therefore.
* Patients with fresh cardiac infarct or impact accumulation (less than six months) were not examined.
Acomplia Zimulti Alli Diet Pill News
Cat Scans Confirm Rimonabant (Acomplia) Reduces Dangerous Abdominal Obesity
Diet Drug Acomplia (Rimonabant) Still Seen as a Winner by Sanofi
Diet Drug Taranabant Produces Weight Loss at One-Tenth the Acomplia Dosage
Acomplia Drug Drug Weight Loss: Carving a Shapely and Slimmer Body
Sanofi Acomplia Drug Hits New Hurdle With Indian Knockoffs
Is Alli a dieter's best friend?
alli diet pill for weight loss orlistat otc pill
Sanofi-Aventis announce the launch of Acomplia in the UAE
Alli Diet Pill Bringing A New Revolution
Acomplia Diet Pill Not a Miracle Its Just a Diet Drug
New diet drug is no miracle, maker says
Sanofi-Aventis "overweight," estimates raised
Raids in Europe Crack Ring Selling Counterfeit Acomplia on Internet
acomplia pille available online
Diet pill danger
Alli Diet Pill Book Launched
Scientists develop 'exercise pill'
Sanofi's Acomplia Approved in Switzerland
Weight-loss drug delayed
Diet Drug Acomplia Seen Unlikely to Get FDA Approval
Buy Diet Pills Acomplia Xenical Reductil
Sanofi says to launch Acomplia in France next month
Analysis: Analysts split on Amylin
Acomplia (Rimonabant) Gets French OK Limited to Obese Diabetics
|
Acomplia
Menu 
